Prostate Enlargement (BPH) — LUTS, Tamsulosin, Finasteride & TURP Guide — Symptoms, Causes & Treatment | MyMedicPlus

Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate gland caused by overgrowth of stromal and epithelial tissue in the transitional zone. The prostate surrounds the urethra at the bladder neck; as it enlarges, it progressively compresses the urethra and causes bladder outlet obstruction (BOO). BPH is one of the most prevalent conditions in ageing men — histological BPH is present in 50% of men aged 50, 70% at 60, and 90% at 85. Symptomatic lower urinary tract symptoms (LUTS) due to BPH affect 25-50% of men in their 60s and increase linearly with age. BPH does not increase prostate cancer risk, though symptoms overlap. Quality of life impact is substantial: nocturia, urinary urgency, and a weakened urinary stream are ranked among the most bothersome symptoms for older men, significantly affecting sleep, work, and wellbeing.

BPH results from progressive hormonal-driven hyperplasia of the prostate transitional zone with ageing. The central mechanism involves testosterone and its more potent intraprostatic metabolite dihydrotestosterone (DHT). DHT is converted from testosterone within prostate stromal cells by 5-alpha-reductase type 2. DHT binds androgen receptors and stimulates prostate cell proliferation and reduces apoptosis — 5-alpha-reductase inhibitors (finasteride, dutasteride) exploit this mechanism therapeutically. An increased oestrogen-to-testosterone ratio with ageing may further drive stromal hyperplasia. Chronic prostatic inflammation is increasingly recognised as a contributor to BPH progression and LUTS severity. Risk factors: advancing age (the strongest risk factor); family history (first-degree relatives have 4-fold higher risk suggesting genetic susceptibility); obesity and metabolic syndrome — abdominal adiposity and insulin resistance correlate with LUTS severity (hyperinsulinaemia stimulates prostate growth through IGF-1); diabetes mellitus; physical inactivity; alcohol consumption; and high dietary animal fat.

LUTS are classified as voiding (obstructive) and storage (irritative) symptoms. Voiding symptoms: weak, slow, or intermittent urinary stream; hesitancy (difficulty initiating voiding — particularly in cold weather or public environments); straining to void; sensation of incomplete bladder emptying; and prolonged time to void. Storage symptoms: urinary frequency (voiding more than every 2 hours); urgency (sudden compelling urge to void difficult to defer — from bladder overactivity secondary to BOO); urge incontinence; nocturia (waking 2+ times per night — often the most bothersome symptom, severely disrupting sleep). International Prostate Symptom Score (IPSS): a validated 7-item questionnaire scored 0-35; mild LUTS: 0-7; moderate: 8-19; severe: 20-35; plus a quality of life impact question (0-6). Post-void residual (PVR) urine volume measured by bladder ultrasound quantifies incomplete emptying; over 150 mL suggests chronic urinary retention.

Clinical assessment: IPSS symptom questionnaire; 3-day bladder diary (voiding frequency, urgency episodes, nocturia); digital rectal examination (DRE) — assesses prostate size (normal 15-25 mL), consistency (smooth and rubbery in BPH; hard, nodular, or asymmetric raises cancer concern), and tenderness. Urinalysis and urine culture: exclude UTI and haematuria. Prostate-specific antigen (PSA): should be offered after counselling — PSA correlates with prostate volume in BPH; an elevated PSA requires cancer risk stratification (PSA density, multiparametric MRI, or urological referral). Uroflowmetry: peak urinary flow rate (Qmax) under 10 mL/s suggests significant obstruction (normal above 15 mL/s); combined with PVR measurement. Transrectal ultrasound (TRUS) or transabdominal prostate ultrasound: measures prostate volume — over 30 mL significant BPH; over 80 mL suggests large gland requiring specific surgical planning (HoLEP preferred over TURP for large prostates). Urodynamic studies (pressure-flow studies): for complex cases to confirm BOO versus detrusor underactivity.

Watchful waiting with lifestyle modification: for mild LUTS (IPSS under 7) — reduce fluid intake in evenings; avoid caffeine and alcohol (bladder irritants); practice double voiding (void, wait 30 seconds, void again); bladder retraining for urgency. Alpha-adrenergic blockers: tamsulosin (0.4 mg daily), alfuzosin, silodosin, or doxazosin — relax smooth muscle in prostate and bladder neck, improving Qmax by 25-30% and reducing IPSS by 4-6 points within 1-2 weeks; first-line for moderate-severe LUTS. Side effects: retrograde ejaculation (tamsulosin 10-28%), postural hypotension (alfuzosin, doxazosin — avoid in hypotensive patients). 5-alpha-reductase inhibitors (5ARIs): finasteride (5 mg daily) and dutasteride (0.5 mg daily) — block DHT synthesis, reducing prostate volume by 20-30% over 6-12 months; effective for large prostates (over 30 mL); reduce 5-year acute urinary retention risk by 57% and surgery risk by 48%; take 6-12 months for full symptomatic benefit. Combination therapy (alpha-blocker plus 5ARI): superior to either alone for large prostates — MTOPS and CombAT trials confirmed. PDE5 inhibitors: tadalafil 5 mg daily — licensed for LUTS with or without erectile dysfunction. Surgical options: transurethral resection of the prostate (TURP) — gold standard for moderate-large BPH; endoscopic resection under spinal or general anaesthesia; improves Qmax by 125% and IPSS by 15+ points; risk of retrograde ejaculation (75%), incontinence (1%), erectile dysfunction (10%). Holmium laser enucleation (HoLEP): preferred for large prostates over 80 mL — lower blood loss and hospital stay. Minimally invasive options (outpatient, preserved ejaculation): Rezum (water vapour thermal therapy), UroLift (prostatic urethral lift — mechanical retraction).

Acute urinary retention (AUR): sudden inability to void — a painful emergency requiring urethral catheterisation and urological assessment; occurs in 2-3% of men with BPH annually; precipitated by cold exposure, alcohol, anticholinergic medications, decongestants (pseudoephedrine), constipation, and immobility. 5ARIs reduce AUR risk by 57% over 5 years. Chronic urinary retention (CUR) with high-pressure retention: large PVR (over 300 mL) causes constant overflow incontinence and back-pressure hydronephrosis leading to chronic obstructive nephropathy and chronic kidney disease — insidious onset, often painless. Urinary tract infections: urinary stasis promotes bacterial colonisation; recurrent UTIs with haematuria and dysuria. Bladder stone formation from stagnant urine. Bladder diverticula from high voiding pressures. Haematuria from rupture of prostatic surface veins — 5ARIs (finasteride) significantly reduce BPH-related haematuria by reducing prostate vascularity.

Regular physical activity reduces BPH risk and LUTS severity — aerobic exercise equivalent to walking 3 hours weekly is associated with a 25% reduction in LUTS severity in observational studies. Maintain a healthy weight: obesity and abdominal adiposity increase prostate growth and LUTS; even 5-10% weight loss improves IPSS by 2-4 points. Dietary modifications associated with reduced LUTS risk: Mediterranean diet (high vegetables, fish, olive oil; low red meat and saturated fat); lycopene-rich foods (tomatoes); and zinc-rich foods. Avoid medications that precipitate urinary symptoms or acute retention: anticholinergics, antihistamines, decongestants (pseudoephedrine, oxymetazoline), tricyclic antidepressants, and antipsychotics — all worsen bladder outlet obstruction. Limit caffeine and alcohol, particularly in evenings. Fluid management: 1.5-2 litres daily with reduced intake after 6 pm to improve nocturia.

See a GP for any lower urinary tract symptoms (nocturia, weak stream, hesitancy, urgency, frequency) affecting quality of life — particularly if you are over 45. Attend A&E immediately for: sudden complete inability to pass urine (acute urinary retention — a painful emergency requiring catheterisation); overflow incontinence with large, painless bladder (chronic urinary retention); or visible blood in urine with clots causing urinary obstruction. See a GP urgently for: haematuria (blood in urine — requires urgent investigation to exclude bladder or prostate cancer); recurrent UTIs with urinary symptoms; or any nocturia causing significantly disrupted sleep or daytime fatigue. All men with LUTS should have a PSA test offered after counselling — to assess prostate cancer risk alongside BPH diagnosis and guide appropriate treatment planning.